Home Medizin Entschlüsselung der Rolle von GPCRs in der Adipositaspathologie für die Arzneimittelentwicklung

Entschlüsselung der Rolle von GPCRs in der Adipositaspathologie für die Arzneimittelentwicklung

von NFI Redaktion

Introducing a new publication for the Acta Materia Medica journal. G protein-coupled receptors (GPCRs) are important potential drug targets for treating metabolic disorders such as obesity. GPCRs interact with multiple transducers, including heterotrimeric G proteins, GPCR kinases (GRKs), and β-arrestins.

GPCR-based agonism has increased the potential for developing novel drugs, preferentially activating therapeutic pathways over pathways leading to undesirable side effects. The obesity epidemic and its metabolic complications continue to pose a major global public health threat, with effective treatment options being limited. The accelerated development of structural techniques such as X-ray crystallography and cryo-electron microscopy has paved the way for understanding how biased agonism, measured at GPCRs, leads to specific downstream physiological responses.

The authors of this article summarize well-validated GPCR targets and outline several new and promising receptors for treating obesity. The importance of deciphering the role of GPCRs in adiposity pathology and biased signal transduction for drug development is highlighted.

Source:

Journal Reference:

Shen, S., et al. (2024) G protein-coupled receptor-mediated signal transduction: Potential drug discovery for facilitating treatment of metabolic disorders. Acta Materia Medica. doi.org/10.15212/AMM-2023-0041.

Related Posts

Adblock Detected

Please support us by disabling your AdBlocker extension from your browsers for our website.